A recent study indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt conventional lifestyle regimens.
Findings released in a prominent medical journal demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these treatments must be informed of the danger of rapid rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of recovery implies a return to starting weight within about 18 months.
Weighing Therapies
The analysis, which reviewed 37 of trials involving thousands of participants, contrasted the effects of these new drugs with older methods.
The team point out that individuals who lose weight through lifestyle changes alone typically see a more gradual creep back—around 100 grams monthly—once they finish.
Understanding the Fast Regain
Doctors propose the way of the jabs accounts for the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels several times higher than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means hunger is unsuppressed, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals contend that, given the likelihood of relapse, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who note that the findings "underscore the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
Users who have stopped the medication report a powerful resurgence of appetite.
"It felt as if something that goes on and you're instantly ravenous," described one woman.
This challenge is compounded if patients have not established sustainable dietary or behavioural changes during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on combined behavioural changes.
